I wonder if others have been thinking along the same lines as me (above), and therefore decided to cut existing positions ahead of the new shares being issued?
If this keeps up, those acquiring new shares through the rights issue will probably hold on and hope for the best, 'cause they'll be taking a hit otherwise.
PS...I maintain my views that roadshows and conferences to nothing for the share price. As I said previously, I'm pretty inexperienced with biotech investments, but my experience with mining shares over the years is that conferences never seem to draw out any meaningful buying (and they always spin a good news story at these things).
NRT Price at posting:
28.0¢ Sentiment: Hold Disclosure: Held
